Longitudinal Knowledge Assessment
Ming Lim, MD, Chair
Dr. Lim has been an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah since October 2018. She currently serves as a member of the Hematology Longitudinal Knowledge Asessment Approval Committee at the American Board of Internal Medicine. She is the recipient of two foundation-sponsored grants to determine the epidemiology and risk factors for inhibitor development in non-severe hemophilia A patients. She has co-authored over 30 peer-reviewed publications.
She is board certified in both Hematology and Medical Oncology. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting patients with congenital bleeding disorders, specifically hemophilia patients with inhibitors.
Dr. Lim earned her medical degree at Cambridge University, England and completed her two-year foundation training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill.
As of July 2022, Dr. Lim reported the following external relationships:
Service on a research-related advisory board for the following companies, with honoraria:
- Dova
- Forma
- Takeda
Dr. Lim serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Society of Hematology, Subcommittee on Stewardship and Systems-Based Hematology, without compensation
- The Hemostasis and Thrombosis Research Society, Board of Directors, Research Colloquium, Trainee Workshop Planning Committee, receiving honoraria
- The National Comprehensive Cancer Network, Cancer-Associated VTE Panel, without compensation
Juliana Alvarez Argote, MD
Dr. Argote is an Assistant Professor in the Department of Medicine, Division of Hematology and Medical Oncology, at the Medical College of Wisconsin (MCW) and the Clement J. Zablocki Veterans’ Administration Medical Center (VAMC) in Milwaukee. She is also a member of the American Society of Gene and Cell Therapy and Chair of the Education Committee. In addition, she serves as the Cancer Liaison Physician for the Cancer Committee of the Clement J. Zablocki VAMC. She is a member of the American Society of Hematology and formerly a member of the ABIM Item-Writing Task Force in hematology. Dr. Argote joined the Hematology LKA Approval Committee in 2023. She is board certified in Internal Medicine, Transfusion Medicine and Blood Banking, Hematology and Medical Oncology. Her professional interests include nonmalignant hematology, sickle cell disease and gene therapy.
Dr. Argote received her medical degree from the Universidad del Valle in Colombia. She completed an internal medicine residency at the University of Connecticut as well as fellowships in transfusion medicine and blood banking at the University of Chicago. She completed a fellowship in hematology and medical oncology at MCW.
As of July 2022, Dr. Argote reported no ongoing external relationships.
Lisa Boggio, MD
Dr. Boggio is an Assistant Professor of Medicine in the Department of Medicine, Division of Hematology and Oncology, Section of Hematology at Rush University Medical Center and Clinical Director of the Rush Hemophilia and Thrombophilia Treatment Center, a federally-funded comprehensive treatment center for children and adults with hemophilia, Von Willebrand disease and other bleeding disorders, as well as a wide range of clotting disorders. She is also a co-director of the consultative hematology service. She is a member of the American Society of Hematology, the Hemophilia Foundation of Illinois, the National Hemophilia Foundation, the World Federation of Hemophilia, the International Society on Thrombosis and Haemostasis, the Hemophilia and Thrombosis Research Society, the American Association of Blood Banks, the American College of Physicians/American Society of Internal Medicine, the American Society of Clinical Apheresis and the Hemophilia and Thrombosis Research Society; she has contributed to several committees within these societies. She is also a member of the Hemophilia Foundation of Illinois Board of Directors and Medical Director of Camp Warren Jyrch. She is a guest reviewer for several journals, including The Journal of Thrombosis and Haemostasis, Drugs, Blood Coagulation and Fibrinolysis, The Journal of the American Medical Association, The American Journal of Cardiology and Haemophilia.
Dr. Boggio has expertise in bleeding and thrombotic disorders, cytopenia, myeloproliferative disorders and myelodysplastic disorders. She has authored numerous publications and was a recipient of the David Green-Hau Kwaan Teaching Award at Northwestern University.
Dr. Boggio graduated from Chicago Medical School in 1993 and completed her residency in internal medicine and a fellowship in hematology and oncology at Northwestern University.
As of March 2021, Dr. Boggio reported the following external relationships:
Funding for clinical trial expenses and staff, paid to Rush University Medical Center, from the following companies:
- Alnylam
- Bayer
- Novo Nordisk
- OctaPharma
- Sanofi
- Takeda
- DuPont
- Pfizer
Service on a research-related advisory board for the following companies, with and honoraria:
- Novo Nordisk
- Sanofi
Dr. Boggio serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- Bleeding Disorders Alliance Illinois, serving as medical director of bleeding disorders camp educational lectures for patient meetings, without compensation.
- International Society on Thrombosis and Haemostasis, education committee member, without compensation.
- Haemostasis and Thrombosis Research Society, grant review committee member, without compensation.
Vince Cataldo, MD
Dr. Cataldo is an Associate Professor of Clinical Medicine at Louisiana State University Health Sciences Center and Section Chief of Hematology and Medical Oncology of Our Lady of the Lake Physician Group in Baton Rouge, Louisiana. He is Board Certified in Internal Medicine, Hematology and Medical Oncology. He previously served as a member and later a mentor of the ABIM Hematology Item-Writing Task Force. Dr. Cataldo received a Bachelor of Science degree in Zoology from Louisiana State University and his medical degree from Louisiana State University Health Sciences Center in New Orleans. He completed internal medicine residency at Louisiana State University Health Sciences Center (Charity Hospital), and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, where he served as Chief Fellow in the final two years of fellowship.
As of August 2023, Dr. Cataldo reported no ongoing external relationships.
Morie Gertz, MD, MACP
Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic in Rochester, Minnesota. He is board certified in Internal Medicine, Hematology and Medical Oncology, and is an active participant in the Maintenance of Certification program. Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and President of Mayo Staff Officers and Councilors. He also formerly chaired the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board, to which he was appointed chair in 2023.
Dr. Gertz has been recognized as a Mayo Distinguished Clinician and in 2014 received the Jan Waldenström Medal for Medical and Scientific Achievements in Waldenström's Macroglobulinemia. He is recognized for contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker across the country.
Dr. Gertz is a Master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, where he graduated Phi Beta Kappa. Dr. Gertz received his medical degree cum laude from Loyola University Chicago’s Stritch School of Medicine in Maywood, Illinois, where he was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and where he was twice voted Resident of the Year.
As of July 2022, Dr. Gertz reported the following external relationships:
Funding for clinical trial expenses and staff, from the following companies:
- Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to the Mayo Clinic
- Ionis, for a trial of iRNA for familial amyloidosis, providing funding for staff and expenses
- Pfizer, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to the Mayo Clinic
- Protega Pharma, for a trial of serum TTR, paid to the Mayo Clinic
Attendance at investigators’ meetings, with compensation as listed from the following company:
- Akcea Therapeutics, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria
Service on data and safety monitoring boards for the following companies, with honoraria:
- AbbVie
- Celgene, for a Phase III trial of venetoclax
Service on a research-related expert panel or advisory board for the following company, with compensation as listed:
- Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria
Research-related consulting for the following company, with honoraria:
- Sanofi
Industry-supported continuing medical education supported by the following, with compensation as listed:
- Alnylam, receiving honoraria
Teaching in industry-sponsored satellite symposia with funding from the following companies, with compensation as listed:
- Johnson & Johnson, receiving honoraria
- Research to Practice, receiving honoraria
Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Society of Hematology, Training Committee, receiving reimbursement for travel expenses
- The Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients
- The International Waldenstrom’s Macroglobulinemia Foundation, receiving reimbursement for travel and other expenses associated with providing lectures to patients
Margaret Kasner, MD, MSCE
Dr. Kasner is the Director of the Leukemia Section at Thomas Jefferson University as well as the medical director of the Cancer Clinical Research Office of the Sidney Kimmel Cancer Center. She also serves on the American Society of Hematology’s Committee on Educational Affairs.
Dr. Kasner is an active hematologist-oncologist specializing in the care of patients with acute leukemias and related disorders. Her clinical and translational research is focused on understanding and improving the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, myeloproliferative neoplasms and associated disorders.
Dr. Kasner earned her medical degree and a master's degree in Clinical Epidemiology and Biostatistics at the University of Pennsylvania. She completed her residency and hematology oncology fellowship at the Hospital of the University of Pennsylvania.
As of July 2022, Dr. Kasner reported the following external relationships:
Funding for clinical trial expenses and staff, paid to Thomas Jefferson University, from the following companies:
- Otsuka
- Gilead
- Pfizer
- Karos/Telios
Service on data and safety monitoring boards for the following company, with honoraria:
- Kronos
Service on a research-related advisory board for the following company, with honoraria:
- Bristol-Myers Squibb
Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:
- Jazz
- Otsuka
Dr. Kasner serves in significant roles with the following organization, receiving reimbursement or compensation as listed:
- American Society of Hematology, Member, Educational Affairs Committee, without compensation
Peter Kouides, MD
Dr. Kouides is the Medical and Research Director of the Mary M. Gooley Hemophilia Center in Rochester, New York, and a Clinical Professor of Medicine at the University of Rochester School of Medicine. In more than 25 years of affiliation with the Mary M. Gooley Hemophilia Center, Dr. Kouides has served as principal investigator (PI) on a number of retrospective and prospective studies focused on the gynecological and obstetrical complications of von Willebrand disease (VWD) and as a local PI on numerous hemophilia surveillance and treatment studies.
Dr. Kouides is Section co-Chair of the American Society of Hematology’s Self-Assessment Program Chapter on Women with Hemostasis and Thrombosis Issues. He is a member of the VWD working group of the National Hemophilia Foundation (NHF) Medical and Scientific Advisory Committee and past and present member of the Medical and Scientific Advisory Council. He is member of the ISTH/WHF/NHF VWD Management Guideline Committee. He is a mentor to the Foundation for Women and Girls with Blood Disorder Learning Action Network. He also directs the World Federation of Hemophilia twinning program between the Mary M. Gooley Hemophilia Center—initially with Bishkek, Kyrgyzstan, from 2009 to 2013 and presently with Kathmandu, Nepal, since 2014. Previously, Dr. Kouides served as President of the Thrombosis and Hemostasis Societies of North America 2018-2020, co-Chair of the Centers of Disease Control Universal Data Collection study of women with bleeding disorders and member of the International Society of Thrombosis and Hemostasis Women’s Health Issues Scientific Subcommittee.
Dr. Kouides has received numerous awards, including:
- 2005: The National Hemophilia Foundation Special Recognition Award for Research in Women with Bleeding Disorders
- 2007: The Rochester General Hospital first annual Dr. Samuel Grove and Dr. Ignaz Semmelweiss “Golden Hand Award”
- 2008: The University of Rochester Primary Care Program in Internal Medicine Teaching Award
- 2009: The National Hemophilia Foundation Physician of the Year Award
- 2010: The Rochester General Hospital Father Norton Award (“Physician of the Year”)
- 2014: The Hemostasis and Thrombosis Research Society Award of Appreciation as Past President
- 2014: The Thrombosis Hemostasis Summit of North America Award of Appreciation as Summit co-Chair
- 2017: The Roswell Park Memorial Cancer Institute Fellows Teaching Award
- 2019: The Hemostasis and Thrombosis Research Society Dr. Joan C. Gill Award for Outstanding Service
- 2019: The Foundation for Women & Girls with Blood Disorders Ann-Marie Nazzaro Award for advancing the mission and vision of the foundation
As of August 2022, Dr. Kouides reported the following external relationships:
Service on data and safety monitoring boards for the following companies, with honoraria:
- Uniqure, serving as data and safety monitoring board chair
- Tremeau Pharmaceuticals, serving as data and safety monitoring board member
Dr. Kouides serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- Thrombosis and Hemostasis Summit of North America, past president, without compensation
- National Hemophilia Foundation, member, medical advisory board, without compensation
- National Blood Clot Alliance, member, medical advisory board, without compensation
Richard Larson, MD
Dr. Richard Larson is Professor of Medicine in the Section of Hematology/Oncology and Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He was a Fellow of the Leukemia Society of America and was granted a Clinical Oncology Career Development Award from the American Cancer Society. He has been a member of the faculty in the Section of Hematology/Oncology and the Comprehensive Cancer Center at the University of Chicago since 1983.
He was Director of the Leukemia Clinical Research Program at the University of Chicago from 1983 to 2000, during which time he established the adult allogeneic bone marrow transplant program at the University of Chicago Medical Center in 1986. He is board certified in Internal Medicine, Hematology, and Medical Oncology, and has served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine.
Between 1997-2011, Dr. Larson was chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB), where he directed a large portfolio of clinical trials and correlative laboratory studies in acute and chronic leukemias. He is currently a member of the National Cancer Institute's Leukemia Steering Committee and the American Board of Internal Medicine’s Hematology Longitudinal Approval Committee.
Dr. Larson is a former Councilor on the Executive Committee of the American Society of Hematology and served as the Treasurer of ASH between 2011-2014. He was awarded the Henry M. Stratton Medal for Clinical Science in 2019. He has been a faculty member at ASH's Clinical Research Training Institute, and he has been an invited speaker at the Highlights of ASH in North America, Latin America, Asia, and the Mediterranean.
He received his medical degree from the Stanford University School of Medicine in 1977, and completed his postdoctoral training in internal medicine, hematology, and medical oncology at the University of Chicago.
As of May 2023, Dr. Larson reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:
- Astellas, for Phase I/II and III clinical trials with gilteritinib for leukemia.
- Celgene, for a Phase III trial of AG221 in leukemia
- Cellectis, for a Phase I clinical trial in acute lymphoblastic leukemia
- Daiichi Sankyo, for a Phase III clinical trial with quizartinib for leukemia
- Gilead, for a Phase III clinical trial of magrolimab in myelodysplastic syndrome
- Novartis, for a Phase III clinical trial with asciminib in chronic myeloid leukemia and for a Phase III clinical trial with nilotinib for leukemia
- Rafael Pharmaceuticals, for a Phase III clinical trial in acute myeloid leukemia
Service on data and safety monitoring boards for the following companies, with honoraria:
- Epizyme, for a Phase II trial of EZH2 inhibitor
- Novartis, for a Phase III clinical trial of MBG453 in myelodysplastic syndrome
- Takeda, for a Phase III clinical trial of ponatinib in chronic myeloid leukemia
Service on a research-related expert panel or advisory board for the following companies, with honoraria:
- CVS, for formulary review
- Novartis, for study management committee for oversight of a phase III trial of nilotinib in leukemia
Consulting on the design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:
- Novartis, for consulting on asciminib
Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:
- Continuing medical education lectures on diagnosis and treatment of hematologic malignant diseases, funded by multiple companies
Work as an author or editor for the following company, with compensation as listed:
- UpToDate®, receiving compensation for authorship and work as an editor
Michael Williams, MD
Dr. Williams joined the Department of Medicine faculty at the University of Virginia (UVA) Emily Couric Clinical Cancer Center, an NCI-designated Cancer Center. He has served in several leadership roles including Chief of the Hematology/Oncology Division. His patient care and research interests include mantle cell lymphoma, other non-Hodgkin lymphomas and CLL, with a focus on targeted agents and immuno-therapeutics. He serves the Scientific Advisory Board of the Lymphoma Research Foundation as an Emeritus member. He was honored by the inaugural LRF Mantle Cell Lymphoma Leadership Award in 2021 and by establishment of the Dr. Michael Williams Abstract Achievement Award for MCL Research.
He is a member of the Eastern Cooperative Oncology Group Lymphoma Core Committee and of the European Mantle Cell Lymphoma Network. Dr. Williams is past Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine (ABIM), a past member of the ABIM Council, and currently serves on the ABIM Hematology Longitudinal Knowledge Assessment Approval Committee. He serves on the editorial boards of the Journal of Clinical Oncology and Annals of Lymphoma, and is Associate Editor for Hematologic Malignancies for the New England Journal Medicine Group Journal Watch Oncology and Hematology. He participates regularly in national and international programs devoted to research and education in lymphoma and CLL.
Dr. Williams received his medical degree from the University of Cincinnati College of Medicine and master of science degree from the Harvard School of Public Health. He completed his medical residency, chief Residency and fellowship at UVA Health.
As of July 2022, Dr. Williams reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to the University of Virginia, from the following companies:
- Allos, receiving funding for clinical trial expenses and staff
- Janssen, receiving funding for clinical trial expenses, salary support and staff
- Kymera, receiving funding for clinical trial expenses and staff
- Pharmacyclics, receiving funding for clinical trial expenses and staff
- TG Therapeutics, receiving funding for clinical trial expenses and staff
Service on a research-related expert panel or advisory board for the following companies, with honoraria:
- AstraZeneca
- Gilead
- Janssen
- Kite Pharma
- Kymera
- TG Therapeutics
Dr. Williams serves in significant roles with the following organization, receiving reimbursement or compensation as listed:
- The Lymphoma Research Foundation, Scientific Advisory Board, Emeritus Member as of June 2021, without compensation
Traditional, 10-Year MOC Exam
Robert T. Means Jr., MD, Chair
Dr. Means, a board certified internist and hematologist, was the former Dean and presently Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.
Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina and was on faculty at the University of Cincinnati and Vanderbilt.
Dr. Means is the Chair of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.
Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.
As of August 2022, Dr. Means reported the following external relationships:
Work as an author or editor for the following companies, with compensation as listed:
- Lippincott Williams & Wilkins/Wolters Kluwer, receiving compensation as an editor for Wintrobe’s Clinical Hematology
- UpToDate®, receiving compensation as an author and editor
Teaching in satellite symposia funded by the following company, with honoraria:
- Pharmacosmos, for a virtual talk to staff about clinical issues in pregnancy-related iron deficiency
Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The Southern Society for Clinical Investigation, Executive Advisory Committee, Member, without compensation
- The Iron Disorders Institute, Medical & Scientific Advisory Board, Member, without compensation
Kelly M. Davidson, MD
Dr. Davidson is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Virginia (UVA), where she practices hematology at the Emily Couric Clinical Cancer Center. She was initially certified in Internal Medicine, Medical Oncology and Hematology, and maintains her certification in Hematology.
Dr. Davidson specializes in a variety of benign and malignant hematologic diseases, with a focus on cellular hematology. She sees patients with myeloproliferative and myelodysplastic disorders, red cell disorders including sickle cell disease, bone marrow failure syndromes, plasma cell dyscrasias, mast cell disorders and disorders of hemostasis and thrombosis. In addition to clinical practice, Dr. Davidson teaches in the second-year medical student course in hematology and plays an active role in resident and fellowship training at UVA. She previously practiced both hematology and oncology at Associates in Oncology/Hematology in Rockville, Maryland.
From 2015 through present, Dr. Davidson has been named to the list of Best Doctors in America. In 2016, she served on the American Board of Internal Medicine (ABIM) Standard Setting Panel for the Hematology Maintenance of Certification Exam, and currently serves as a member of the ABIM Hematology Board Exam Committee. She has been a member of the American Society of Hematology since 2003.
Dr. Davidson received a biology degree summa cum laude from Georgetown University and her medical degree from Washington University in St. Louis. She completed internship and residency in internal medicine at Beth Israel Deaconess Medical Center in Boston and fellowship training in hematology and oncology at UVA.
As of September 2022, Dr. Davidson reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the University of Virginia, from the following company:
- Takeda
Service on a research-related advisory board for the following companies, with honoraria:
- Blueprint Medicines
- Sanofi
Dr. Davidson also reported receiving grant funding from the Virginia Department of Health to support an adult sickle cell program.
Chancellor E. Donald, MD
Dr. Donald currently practices at Lourdes Oncology Associates in Lafayette, Louisiana. In 2010, he joined the practice and became Managing Partner in 2014. Additionally, at Our Lady of Lourdes Regional Medical Center, he functions as Medical Director of the oncology service line, a member of the Medical Executive Committee and as a Trustee on the Board of Directors.
Dr. Donald is board certified in Internal Medicine, Hematology and Medical Oncology. He serves on the American Board of Internal Medicine’s Hematology Exam Board Committee.
Dr. Donald advocates for patients with malignancies and hematologic disorders. He is currently President of the Louisiana Oncology Society. He has been appointed to the Board of Directors of the Community Oncology Alliance. In 2013, he was given the Spirit of Hope Award by the American Cancer Society. The American Society of Hematology (ASH) selected him for its Committee on Practice. He also holds the position of ASH’s alternate delegate to the American Medical Association’s House of Delegates. Since 2012, he has served as the Hematology Representative for Louisiana for the Medicare Carrier Advisory Committee (CAC). He served as co-Chair of the 2017 Annual CAC meeting at the American Society of Clinical Oncology headquarters and was again selected for that role for the 2018 annual meeting at the ASH headquarters. For the 2017 Annual Meeting of ASH, he served as the clinical designee to the Program Committee.
Dr. Donald graduated magna cum laude from Florida A&M University and received his medical degree from the University of Miami School of Medicine. He completed his internship, residency and fellowship at Tulane University. He served as Chief Resident and Chief Fellow there and currently holds the position of Clinical Assistant Professor within Tulane’s Department of Hematology/Oncology.
As of May 2023, Dr. Donald reported the following external relationships:
Service on a research-related expert panel or advisory board for the following company, receiving honoraria:
- Curio Sciences, for serving on an advisory board discussing therapeutics treatment strategies of lung cancer
Dr. Donald serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- The American Society of Hematology, Standing Member of Committee on Practice; Delegate to the House of Delegates of the American Medical Association; receiving reimbursement for travel expenses
- The Community Oncology Alliance, Board of Directors, Member, without compensation
- Taking Aim at Cancer in Louisiana Initiative, Chief Medical Officer, without compensation
- Louisiana Oncology Society, Immediate Past President, without compensation
Elizabeth Hexner, MD
Dr. Hexner is a physician scientist with an interest in education and two major research interests in malignant hematology: the first is in cellular therapies and hematopoietic stem cell transplantation, and the second is in myeloproliferative neoplasms (MPN). Both have a translational focus and align with her clinical roles as Medical Director of the Center for Cellular Immunotherapies and as Director of the University of Pennsylvania MPN program. In MPN she has designed and executed preclinical studies of janus kinase (JAK) inhibitors and also used bioassays and correlative studies in MPN patients treated with JAK inhibitors focused on resistance.
Her work in MPN, cellular therapies, stem cell transplantation, primary cell systems and preclinical and clinical investigation allows me to intersect productively with basic science, transfusion medicine, regulatory, and clinical colleagues. In another major area of focus. Dr. Hexner serves as the Associate Director of the National Institutes of Health Clinical and Translational Science Awards-funded Masters in Translational Research program at the University of Pennsylvania, serving on the education, selection, and curriculum committees and overseeing a cohort of candidates as a programmatic mentor.
Dr. Hexner received her medical degree from Columbia University. She completed her residency at New York Presbyterian/Columbia University Medical Center and her fellowship at the Hospital of the University of Pennsylvania.
As of August 2022, Dr. Hexner reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to the University of Pennsylvania, from the following companies:
- Blueprint Medicines, receiving funding for staff and expenses.
- TMUNITY, receiving funding for salary support.
Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:
- Blueprint Medicines
Research-related advisory boards for the following companies, with compensation for travel expenses and honoraria:
- Pharmessentia
- AbbVie
Cindy Leissinger, MD
Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.
In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.
Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Hemostasis, and the Hemostasis and Thrombosis Research Society.
Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at the National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.
As of June 2023, Dr. Leissinger reported the following external relationships:
Funding for clinical trial expenses, salary support and staff, paid to Tulane University, from the following companies:
- Biomarin, for a study of a Factor VIII gene therapy
- Roche, for a study of a new Factor VIII mimetic protein
Service on a research-related expert panel or advisory boards for the following companies, with honoraria:
- CSL Behring
- Pfizer
Service on data and safety monitoring boards for the following company, with honoraria:
- Editas, for a data monitoring committee for gene therapy
Teaching in satellite symposia funded by the following companies, with compensation for travel expenses and honoraria:
- Biomarin, receiving reimbursement for travel expenses and honoraria
- Octapharma, receiving honoraria
Danielle Shafer, MD
Dr. Shafer is the Director for Malignant Hematology Clinical Research at Inova Schar Cancer Institute in Fairfax, Virginia. Previously, she was Assistant Professor in the Division of Hematology, Oncology and Palliative Care at Virginia Commonwealth University. She also served on the American Board of Internal Medicine's Hematology Exam Committee and joined the Hematology Traditional, 10-Year MOC Exam Approval Committee in 2023.
Dr. Shafer is board certified in Internal Medicine, Hematology and Medical Oncology. Her clinical interest lies in the treatment of leukemia and lymphoma as well as in clinical trials. Her research interest has been focused on early therapeutics in acute myeloid leukemia.
Dr. Shafer received her medical degree from Chicago College of Osteopathic Medicine. She completed her fellowship at Fox Chase Cancer Center and her residency at Loyola University Medical Center.
As of September 2020, Dr. Shafer reported no external relationships.